Search alternatives:
aromatic decrease » dramatic decrease (Expand Search)
somatic decrease » dramatic decrease (Expand Search)
small decrease » small increased (Expand Search)
Showing 701 - 720 results of 2,241 for search '((aromatic decrease) OR (((somatic decrease) OR (small decrease))))', query time: 0.35s Refine Results
  1. 701

    Table 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.docx by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  2. 702

    Data Sheet 2_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.pdf... by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  3. 703

    Data Sheet 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.zip... by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  4. 704
  5. 705
  6. 706
  7. 707
  8. 708
  9. 709
  10. 710
  11. 711
  12. 712
  13. 713
  14. 714
  15. 715
  16. 716

    Image 2_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif by Wenhao Wang (515852)

    Published 2025
    “…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
  17. 717

    Image 4_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif by Wenhao Wang (515852)

    Published 2025
    “…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
  18. 718

    Data Sheet 1_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.zip by Wenhao Wang (515852)

    Published 2025
    “…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
  19. 719

    Image 1_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif by Wenhao Wang (515852)

    Published 2025
    “…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
  20. 720

    Image 3_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif by Wenhao Wang (515852)

    Published 2025
    “…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”